Global Leber Congenital Amaurosis (LCA) Market Growth (Status and Outlook) 2025-2031

According to this study, the global Leber Congenital Amaurosis (LCA) market size will reach US$ million by 2031.

Leber congenital amaurosis is a kind of autosomal recessive genetic disease, it is the main genetic disease that brings about children blindness, accompany mental nerve symptom, wait like intellectual inferior, hearing obstacle, epilepsy, conus cornea can happen when some age is older or spherical cornea.

United States market for Leber Congenital Amaurosis (LCA) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Leber Congenital Amaurosis (LCA) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Leber Congenital Amaurosis (LCA) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Leber Congenital Amaurosis (LCA) players cover AmpliPhi Biosciences, Editas Medicine, Novelion Therapeutics, ProQR Therapeutics, Spark Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Leber Congenital Amaurosis (LCA) Industry Forecast” looks at past sales and reviews total world Leber Congenital Amaurosis (LCA) sales in 2024, providing a comprehensive analysis by region and market sector of projected Leber Congenital Amaurosis (LCA) sales for 2025 through 2031. With Leber Congenital Amaurosis (LCA) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Leber Congenital Amaurosis (LCA) industry.

This Insight Report provides a comprehensive analysis of the global Leber Congenital Amaurosis (LCA) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Leber Congenital Amaurosis (LCA) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Leber Congenital Amaurosis (LCA) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Leber Congenital Amaurosis (LCA) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Leber Congenital Amaurosis (LCA).

This report presents a comprehensive overview, market shares, and growth opportunities of Leber Congenital Amaurosis (LCA) market by product type, application, key players and key regions and countries.

Segmentation by Type:
Infantile Type
Juvenile Type

Segmentation by Application:
Hospitals
Eye Clinics
Medical Research Institute
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AmpliPhi Biosciences
Editas Medicine
Novelion Therapeutics
ProQR Therapeutics
Spark Therapeutics

Please note: The report will take approximately 2 business days to prepare and deliver. Show more